Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma (DATUM)

Central Hospital, Nancy, France

Status: Completed

Conditions: Meningioma of Brain

Treatments: Diagnostic Test: tumoral dosimetry by scintigraphy

Study type: Observational

Funder types: Other

Identifiers

NCT06614205

2024PI102

Details and patient eligibility

About

The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.

Full description

Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment.

Enrollment: 11 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients treated for menigioma at nancy hospital
• patients who performed 3 scintigraphics exams during there treatment

Exclusion criteria

• patients deprived of liberty
• patient who refused to collect data retrospectively

Trial design

11 participants in 1 patient group

Patients treated with 177Lu-DOTATATE for meningioma

Description:

Patients treated with 177Lu-DOTATATE for meningioma at the Nancy's hospital who met the treatment criteria of the Compassionate Prescribing Framework and received a scintigraphy at D1, D4 and D7 (± 1 day)

Treatment:

Diagnostic Test: tumoral dosimetry by scintigraphy